Seprafilm is used as an adjunct to reduce the incidence, extent and severity of adhesions in pelvic and abdominal surgeries, according to the company. It is commercially available in the U.S., Japan, China, South Korea, France and other countries.
“We are excited to bring Seprafilm products, alongside our leading hemostat and sealant portfolio, to our surgeon and hospital customers around the world,” general manager of Baxter’s advanced surgery business Wil Boren said in a news release. “As we begin the integration process, our dedicated surgery commercial team is focused on working with customers and distributors to ensure a smooth transition.”
The deal was originally announced in December last year where Baxter said it expected to sell about $100 million of Seprafilm products in the 12 months after the close of the deal.
The announcement comes after Baxter said last week that its income for the past four years may have been overstated by $276 million.